Day 2 at #ASCO2026! A strong showing from @MelanomaAus. Here are our poster highlights with my great colleagues Ines da Silva & Alex van Akkooi.   My NeoIRENIE trial in progress - a trial designed to rapidly answer a critical question for the field can we use our biomarker that predicts who is in the ‘third space’ (those that dies for melanoma) and give them our best drugs upfront early-on in their cancer journey.  A true MIA multidisciplinary trial, and now open, expanding across Australia and internationally. MSLT-3  - Alex van Akkooi's MIA-led surgical trial opening globally.  Is less surgery OK for stage III neoadjuvant melanoma treated patients? Ines Da Silva’s leading work on the dynamic tool predicting recurrence on and off adjuvant immunotherapy in early-stage melanoma. She also presented on PD-1 vs Ipi+Nivo in uveal melanoma which builds towards a melanoma oral on tomorrow. I was delighted to also present the updated brenetafusp (ImmTAC) data, a molecule that bridges T cells (immune cell) directly to tumour cells and showing activity in the 'third space’.  The #science is moving! #melanoma @ASCO @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @ausoftheyear